626 305 5900 | Phone
626 305 0350 | Fax

111 W. Lemon Ave.
Monrovia, CA 91016

www.xencor.com

04 August 2021

Re: Clinical Study XmAb5871-06

To Whom It May Concern:

The purpose of this memo is to confirm the status of clinical study XmAb5871-06. The study was not initiated in any EU country, no clinical sites were activated, and no patients were enrolled. The termination of the study was not based on grounds of safety, thus there was no change to the overall risk benefit assessment of XmAb5871-06.

Early termination was based on the Sponsor's decision to reconcile feedback from various global regulatory agencies regarding the study into a single protocol, and to refine the endpoints to accommodate feedback. The general investigation plan for XmAb5871-06 is under evaluation.

Sincerely,
Alex Courtney
Director, Regulatory Affairs
Xencor, Inc.